⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NVS News
Novartis AG
Superior Efficacy and Long-acting: LongBio Announces Positive Topline Results from Phase II CSU Trial of Next-Generation Anti-IgE Therapy, LP-003 in Head-to-Head Comparison with Xolair®
prnewswire.com
NVS
AI in Clinical Trials Market Research 2026: Market to Reach $18.62 Billion by 2040 with IQVIA, Medidata, IBM Watson, Oracle, and Phesi Leading Through Integrated Data and Patient Matching Platforms
globenewswire.com
IQV
DSY
IBM
ORCL
PFE
NVS
AI
Your Kidneys Count: American Kidney Fund Urges Americans to Protect Their Health this Kidney Month
globenewswire.com
AMGN
ARGX
NVS
TVTX
VRTX
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
globenewswire.com
NVS
RNA
Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)
globenewswire.com
NVS
SPARK NS Selects Nine Projects to Receive in Total Up to $18 Million in Funding to Advance Academic Discoveries in Autism and Parkinson’s Disease from the Lab to the Clinic
globenewswire.com
NVS
MRK
BMY
LLY
ABBV
JNJ
AZN
GILD
BIIB
REGN
AMGN
VRTX
Age Related Macular Degeneration Market to Reach $16.2 billion by 2033, Globally, by 2034 at 5% CAGR: Allied Market Research
prnewswire.com
REGN
NVS
ROG
BIIB
CHRS
SNY
APLS
BHC
IONS
Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients
globenewswire.com
NVS
Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients
globenewswire.com
NVS
Novartis AG Enterprise Technology Report 2025: Digital Transformation Strategies, Innovation Programs, Technology Initiatives, Partnerships, Investment & Acquisition, Network Map
globenewswire.com
NVS